SBIR AND STTR FUNDING
OPPORTUNITIES
OPPORTUNITIES
Non-dilutive funding for early-stage research and development.
[Omnibus Solicitations] [Specific Opportunities]
SBIR and STTR grant funding opportunities offer small business entrepreneurs a chance to obtain non-dilutive funding for early-stage research and development. Applications are accepted three times a year.
NIH advertises the availability of grant support through notices of funding opportunities (NOFOs), previously referred to as funding opportunity announcements (FOAs).
More information on HHS SBIR contracts is available on the NIH SBIR contracts webpage.
Helpful Tips
- Follow these step-by-step instructions to learn how to apply for these funding opportunities, including resources on how to prepare your application.
- Read Program Descriptions and Research Topics.
- Refer to SBA-approved waiver eligible topics.
- Watch this NIH SBIR/STTR webinar from November 2024.
Omnibus Solicitations (Parent Announcements)
Researcher-initiated ideas are proposed via the SBIR and STTR Omnibus grant solicitations. These funding opportunities do not specify a topic, though they link to identified topics of interest for each participating awarding component. Most small business applications to NIH are submitted to the Omnibus solicitations.
Read the Program Descriptions and Research Topics to understand the awarding components, their topics of interest, and staff contacts. For topics that require additional funding to reach the marketplace, please refer to our list of SBA-approved waiver-eligible topics.
Standard Application Due Dates are September 5, January 5, and April 5. Due dates that fall on weekends or Federal holidays are moved to the next business day.
| Title | Notice/FOA Number | Organization | Release Date | Due Date(s) | Expiration Date | Clinical Trials |
|---|---|---|---|---|---|---|
| PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) | PA-24-246 | NIH | 07/03/2024 | Multiple dates, see announcement....(see announcement for full details) | 09/06/2025 | Required |
| PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) | PA-24-247 | NIH | 07/03/2024 | Multiple dates, see announcement....(see announcement for full details) | 09/06/2025 | Not Allowed |
| PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) | PA-24-248 | NIH | 07/03/2024 | Multiple dates, see announcement....(see announcement for full details) | 09/06/2025 | Required |
| PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) | PA-24-245 | NIH | 07/03/2024 | Multiple dates, see announcement....(see announcement for full details) | 09/06/2025 | Not Allowed |
Specific Funding Opportunities
Some SBIR/STTR grant solicitations are focused on specific research areas. Some specific NOFOs, identified as RFAs (Requests for Applications) or PASs (Program Announcements with Set-aside funds), have funding set-aside in the Institute/Center's budget for that targeted program.
| Title | Notice/FOA Number | Organization | Release Date | Due Date(s) | Expiration Date | Clinical Trials |
|---|---|---|---|---|---|---|
| Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) | PAS-22-197 | NIANINDS | 06/21/2022 | 09/06/2025 | Optional | |
| Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional) | PAS-22-196 | NIANINDS | 06/21/2022 | 09/06/2025 | Optional | |
| Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) | PAR-24-098 | NINDS | 01/22/2024 | Multiple dates, see announcement....(see announcement for full details) | 06/26/2026 | Optional |
| Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) | PAR-24-294 | NINDSNCCIHNEINIANIAAANIDANIDCRNIEHSNIMHOBSSR | 10/01/2024 | Multiple dates, see announcement....(see announcement for full details) | 08/19/2027 | Optional |
| Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) | PAR-24-063 | NINDSNCCIHNEINIANIAAANICHDNIDANIDCRNIMHOBSSR | 11/01/2023 | 08/19/2026 | Optional | |
| Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) | PAR-24-096 | NINDS | 01/22/2024 | Multiple dates, see announcement....(see announcement for full details) | 06/23/2026 | Optional |
| HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed) | PAR-23-069 | NINDSNCATSNCCIHNEINIAMS | 01/03/2023 | 09/06/2025 | Not Allowed | |
| Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed) | PAR-23-267 | NCATS | 04/18/2023 | Multiple dates, see announcement....(see announcement for full details) | 06/07/2025 | Not Allowed |
| Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed | PAR-23-268 | NCATS | 04/18/2023 | 06/07/2025 | Not Allowed | |
| Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) | RFA-MD-24-006 | NIMHDNCATSNHLBINIANIBIBNIDCRNIDDKNINDSNINR | 03/08/2024 | Multiple dates, see announcement....(see announcement for full details) | 12/10/2026 | Optional |
| Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed) | PAR-23-032 | NIAMS | 10/26/2022 | 09/06/2025 | Not Allowed | |
| Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed) | RFA-TR-23-017 | NCATS | 11/21/2023 | Multiple dates, see announcement....(see announcement for full details) | 02/24/2026 | Not Allowed |
| Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed) | RFA-TR-23-018 | NCATS | 11/21/2023 | Multiple dates, see announcement....(see announcement for full details) | 02/24/2026 | Not Allowed |
| NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required) | PAR-24-066 | NEI | 12/01/2023 | Multiple dates, see announcement....(see announcement for full details) | 01/08/2027 | Required |
| NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional) | PAR-25-133 | NINDS | 11/12/2024 | Multiple dates, see announcement....(see announcement for full details) | 09/06/2027 | Optional |
| NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) | RFA-HL-26-014 | NHLBI | 11/18/2024 | Not Applicable...(see announcement for full details) | 02/27/2027 | Optional |
| NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) | RFA-HL-26-015 | NHLBINCATS | 11/18/2024 | Not Applicable...(see announcement for full details) | 02/27/2027 | Optional |
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required) | PAR-24-099 | NIAID | 01/29/2024 | Multiple dates, see announcement....(see announcement for full details) | 01/14/2027 | Required |
| NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required) | PAR-24-044 | NINDS | 11/27/2023 | Multiple dates, see announcement....(see announcement for full details) | 09/06/2026 | Required |
| NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required) | PAR-23-311 | NINDS | 11/27/2023 | Multiple dates, see announcement....(see announcement for full details) | 09/06/2026 | Required |
| NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional) | PAR-24-221 | NINDS | 06/20/2024 | Multiple dates, see announcement....(see announcement for full details) | 04/06/2027 | Optional |
| NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed) | PAR-24-222 | NINDS | 06/21/2024 | Not Applicable...(see announcement for full details) | 04/06/2027 | Not Allowed |
| Notice of Special Interest (NOSI): Epigenetic Modulation of HBV cccDNA and integrated HBV DNA (iDNA): Implications for Epigenetic Treatment Strategies Against HBV in HIV/HBV Co-Infection | NOT-AI-24-050 | NIAID | 06/28/2024 | 05/08/2027 | Not Allowed | |
| Notice of Special Interest (NOSI): The Road to Prevention of Stillbirth | NOT-HD-23-021 | NICHD | 10/03/2023 | 11/17/2026 | Optional | |
| Notice of Special Interest (NOSI): Translating Biomaterials-Based Technologies to Commercially Viable Products | NOT-EB-24-001 | NIBIBNCATSNCCIHNHLBINIDCR | 03/29/2024 | 04/06/2027 | Optional | |
| Notice of Special Interest (NOSI): Advancing Biomedical Research in Pulmonary Non-Tuberculous Mycobacterial (NTM) Infections | NOT-AI-23-050 | NIAID | 06/27/2023 | 07/17/2026 | Optional | |
| Notice of Special Interest (NOSI): Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics | NOT-AI-23-001 | NIAIDNCINIBIB | 11/23/2022 | 01/08/2026 | Not Allowed | |
| Notice of Special Interest (NOSI): Advancing Genomic Medicine Research through Small Businesses | NOT-HG-24-002 | NHGRI | 10/11/2023 | 09/07/2026 | Not Allowed | |
| Notice of Special Interest (NOSI): Advancing Genomic Medicine Research through Small Businesses | NOT-HG-24-016 | NHGRI | 02/14/2024 | 09/07/2026 | Optional | |
| Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application | NOT-HG-24-036 | NHGRI | 07/25/2024 | 01/10/2027 | Not Allowed | |
| Notice of Special Interest (NOSI): Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42, R43/R44 Clinical Trial Not Allowed) | NOT-DE-21-012 | NIDCR | 09/01/2021 | 09/05/2025 | Not Allowed | |
| Notice of Special Interest (NOSI): Advancing Precision Imaging for Enhanced Diagnosis and Treatment of Oral Lesions | NOT-DE-25-034 | NIDCR | 08/30/2024 | 09/08/2027 | Optional | |
| Notice of Special Interest (NOSI): Advancing Research for Tickborne Diseases (TBDs) | NOT-AI-23-013 | NIAIDNIAMSNIMHNINDS | 11/25/2022 | 01/08/2026 | Optional | |
| Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine | NOT-AI-23-007 | NIAID | 11/25/2022 | 01/08/2026 | Optional | |
| Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine | NOT-AI-23-031 | NIAID | 02/23/2023 | 01/15/2026 | Optional | |
| Notice of Special Interest (NOSI): Development of Functional Assay Sites to Evaluate Candidate -Omics Variants Associated with Heart, Lung, Blood, or Sleep Disease (R01, R41, R42, R43, R44) | NOT-HL-23-066 | NHLBI | 01/31/2023 | 09/08/2026 | Optional | |
| Notice of Special Interest (NOSI): Development of Imaging Techniques for High Resolution and Functional Scanning of In Vivo Human Sensory and Communication Systems | NOT-DC-24-025 | NIDCD | 03/22/2024 | 05/08/2027 | Optional | |
| Notice of Special Interest (NOSI): Development of Innovative Informatics and Data Science Technologies, Tools, and Methods for Vision Research | NOT-EY-23-005 | NEI | 04/03/2023 | 02/16/2026 | Not Allowed | |
| Notice of Special Interest (NOSI): Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults | NOT-MH-23-250 | NIMH | 05/19/2023 | 09/08/2026 | Optional | |
| Notice of Special Interest (NOSI): Discovery and Development of Oral Small-molecule Direct-acting Antivirals Targeting Viruses of Pandemic Potential | NOT-AI-24-053 | NIAID | 06/27/2024 | 07/17/2027 | Not Allowed | |
| Notice of Special Interest (NOSI): Epidemiology and Prevention of Alcohol Misuse in Understudied Young Adult Populations; Military, Workforce, and Community College | NOT-AA-22-001 | NIAAA | 12/09/2021 | 09/09/2025 | Optional | |
| Notice of Special Interest (NOSI): HEAL Initiative: Development and Translation of Diagnostic and Therapeutic Devices via Blueprint MedTech | NOT-NS-24-075 | NINDSNCCIHNCINIANIAAANIAMSNIBIBNICHDNIDANIDCRNIDDKNIMH | 08/08/2024 | 02/29/2028 | Optional | |
| Notice of Special Interest (NOSI): Improving Adherence to Treatment and Prevention Regimens and Maintenance of Health Behaviors to Promote Health | NOT-OD-24-146 | OBSSRNCCIHNCINEINHLBINIANIDANIMHNIMHDNINROARODPORWH | 06/24/2024 | 07/14/2027 | Optional | |
| Notice of Special Interest (NOSI): Innovative Technologies to develop novel tools to prevent and treat HIV in underserved populations | NOT-MH-23-200 | NIMH | 07/18/2023 | 01/06/2027 | Optional | |
| Notice of Special Interest (NOSI): Optimization of Data Storage and Utilization for the Sequence Read Archive (SRA) | NOT-GM-23-015 | NIGMSNLMODSS | 12/14/2022 | 12/19/2025 | Optional | |
| Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services | NOT-MH-22-110 | NIMHNIDAORWH | 02/08/2022 | 05/08/2025 | Optional | |
| Notice of Special Interest (NOSI): Promoting Language and Communication in Minimally Verbal/Non-Speaking Individuals with Autism | NOT-DC-23-009 | NIDCD | 04/03/2023 | 06/06/2026 | Optional | |
| Notice of Special Interest (NOSI): Promoting Research and Development of Vaccines Against Enteric Viruses | NOT-AI-23-048 | NIAID | 06/15/2023 | 07/17/2026 | Optional | |
| Notice of Special Interest (NOSI): Quantum Sensing in Biomedical Applications (SBIR/STTR) | NOT-EY-24-014 | NEINCATSNCINHLBINIBIB | 09/20/2024 | 01/27/2027 | Optional | |
| Notice of Special Interest (NOSI): Research to Stimulate Development of Diagnostics, Therapeutics, and Vaccines for Herpes Simplex Virus (HSV) | NOT-AI-24-028 | NIAID | 03/27/2024 | 04/06/2027 | Not Allowed | |
| Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH) | NOT-AI-24-007 | NIAIDNCATSNCI | 02/02/2024 | 01/06/2027 | Not Allowed | |
| Notice of Special Interest (NOSI): SBIR/STTR High-Priority Areas for Digital Mental Health Innovations | NOT-MH-24-120 | NIMH | 11/29/2023 | 01/06/2027 | Optional | |
| Notice of Special Interest (NOSI): SBIR/STTR Program Priorities to Bridge Gaps in Advancing the NIMH Mission | NOT-MH-24-110 | NIMH | 11/29/2023 | 01/06/2027 | Optional | |
| Notice of Special Interest (NOSI): Small Business Digital Technologies for Early Detection, Characterization and Monitoring of Senescence-Related Changes | NOT-AG-23-004 | NIA | 02/07/2023 | 01/06/2026 | Optional | |
| Notice of Special Interest (NOSI): Small Business Initiatives for Innovative tools and Technologies for Improving Outcomes for Maternal Health | NOT-EB-23-005 | NIBIBNCATSNHLBINIAMSNIMHNIMHDNINDSORWH | 07/26/2023 | 09/06/2026 | Optional | |
| Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications. | NOT-EB-23-002 | NIBIBNCCIHNCINHLBINIANIAIDNICHDNIGMS | 04/14/2023 | 05/17/2026 | Optional | |
| Notice of Special Interest (NOSI): Towards Developing a Cure for HBV in HIV/HBV Co-Infection | NOT-AI-22-043 | NIAID | 04/29/2022 | 05/08/2025 | Not Allowed | |
| Notice of Special Interest (NOSI): Translation of BRAIN Initiative Technologies to the Marketplace | NOT-MH-24-115 | NIMHNCCIHNEINIANIAAANIBIBNICHDNIDANIDCDNINDS | 01/08/2024 | 04/06/2027 | Not Allowed | |
| Notice of Special Interest (NOSI): Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives | NOT-AI-23-076 | NIAID | 10/31/2023 | 07/17/2026 | Not Allowed | |
| Notice of Special Interest (NOSI): Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives | NOT-AI-23-049 | NIAID | 06/23/2023 | 07/17/2026 | Not Allowed | |
| Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers | NOT-CA-23-004 | NCI | 10/17/2022 | 07/02/2025 | Optional | |
| Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence/Machine Learning Tools for Improved Assessment in Biomedical and Behavioral Research | NOT-CA-24-031 | NCINHLBINIANIDANIMHNINROBSSRODSS | 02/15/2024 | 07/06/2025 | Optional | |
| Notice of Special Interest: Development and Implementation of Clinical Informatics Tools to Enhance Patients Use of Genomic Information | NOT-HG-22-011 | NHGRI | 01/06/2022 | 12/31/2025 | Optional | |
| Notice of Special Interest: Development of Radiotracers for Diagnosis and Clinical Studies in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) | NOT-AG-22-032 | NIA | 09/28/2022 | 09/05/2025 | Optional | |
| Notice of Special Interest: Small Business Solutions to Assist Genomics-Enabled Learning Health Systems (gLHS) | NOT-HG-24-040 | NHGRI | 09/04/2024 | 09/06/2027 | Optional | |
| Notice of Special Interest: Small Business Solutions to Enable Regional Genomic Medicine eConsult Services | NOT-HG-24-041 | NHGRI | 09/04/2024 | 09/06/2027 | Optional | |
| Notice of Special Interest: Womens Health Research | NOT-OD-24-079 | ORWHFICNCATSNCCIHNCINEINHGRINHLBINIANIAAANIAIDNIAMSNIBIBNICHDNIDANIDCDNIDCRNIDDKNIEHSNIGMSNIMHNIMHDNINDSNINRNLMOAROBSSRODPODSODSS | 03/26/2024 | 11/05/2027 | Optional | |
| SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required) | PAR-23-220 | ODNEINHLBINIANIAAANIDCDNIMH | 07/12/2023 | Multiple dates, see announcement....(see announcement for full details) | 09/06/2025 | Required |
| SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed) | PAR-23-219 | ODNCATSNCINEINHGRINHLBINIAAANIAIDNIAMSNIBIBNIDCDNIDCRNIDDKNIEHSNIMHNINDS | 07/12/2023 | Multiple dates, see announcement....(see announcement for full details) | 09/06/2025 | Not Allowed |
| Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional) | RFA-DA-25-047 | NIDA | 09/28/2023 | 03/14/2026 | Optional | |
| Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) | RFA-DA-25-048 | NIDA | 09/28/2023 | 03/14/2026 | Optional | |
| Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) | PAR-24-133 | NIHNCATSNCCIHNEINHGRINHLBINIANIAAANIAMSNICHDNIDANIDCDNIDCRNIEHSNIGMSNINRNLM | 04/25/2024 | Multiple dates, see announcement....(see announcement for full details) | 04/06/2027 | Not Allowed |
| Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required) | PAR-24-134 | NIHNCCIHNEINHGRINHLBINIANIAAANICHDNIDANIDCDNINRNLM | 04/25/2024 | Multiple dates, see announcement....(see announcement for full details) | 04/06/2027 | Required |
| Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed) | PAR-24-131 | NIHNCATSNCCIHNEINHGRINHLBINIANIAAANIAMSNICHDNIDANIDCDNIDCRNIDDKNIEHSNIGMSNINRNIOSHNLM | 04/25/2024 | Multiple dates, see announcement....(see announcement for full details) | 04/06/2027 | Not Allowed |
| Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required) | PAR-24-132 | NIHNCCIHNEINHGRINHLBINIANIAAANICHDNIDANIDCDNINRNIOSHNLM | 04/26/2024 | Multiple dates, see announcement....(see announcement for full details) | 04/06/2027 | Required |
| Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) | RFA-MD-24-007 | NIMHDNCATSNIBIBNIDCRNINDSNINR | 03/08/2024 | Multiple dates, see announcement....(see announcement for full details) | 12/10/2026 | Optional |
